US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6429221B1
(en)
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
DE69717831T3
(de)
*
|
1996-07-24 |
2018-08-30 |
Celgene Corp. |
Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
DE19703763C1
(de)
*
|
1997-02-01 |
1998-10-01 |
Gruenenthal Gmbh |
Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
|
US5955476A
(en)
*
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
SK7382000A3
(en)
*
|
1997-11-18 |
2000-12-11 |
Celgene Corp |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use
|
CN100390163C
(zh)
*
|
1998-03-16 |
2008-05-28 |
赛尔金有限公司 |
2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途
|
ES2250121T3
(es)
|
1999-03-18 |
2006-04-16 |
Celgene Corporation |
1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias.
|
DE19917195B4
(de)
*
|
1999-04-16 |
2006-09-28 |
Immatics Biotechnologies Gmbh |
Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
ATE374609T1
(de)
*
|
2000-11-30 |
2007-10-15 |
Childrens Medical Center |
Synthese von 4-aminothalidomid enantiomeren
|
US20040058956A1
(en)
*
|
2000-12-11 |
2004-03-25 |
Yohko Akiyama |
Pharmaceutical composition having an improved water solubility
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
WO2002068414A2
(en)
*
|
2001-02-27 |
2002-09-06 |
The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
JP4494013B2
(ja)
*
|
2001-08-06 |
2010-06-30 |
ザ チルドレンズ メディカル センター コーポレイション |
窒素置換サリドマイド誘導体の合成及び抗腫瘍活性
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
CN1697655B
(zh)
|
2002-05-17 |
2013-09-18 |
细胞基因公司 |
使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
FR2845994B1
(fr)
*
|
2002-10-18 |
2006-05-19 |
Servier Lab |
Nouveaux derives de benzo[e][1,4]oxazino[3,2-g]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
AU2003286663B2
(en)
*
|
2002-10-24 |
2009-08-13 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
NZ540186A
(en)
*
|
2002-10-31 |
2008-03-28 |
Celgene Corp |
Composition for the treatment of macular degeneration
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
CH696542A5
(de)
*
|
2003-07-09 |
2007-07-31 |
Siegfried Ltd |
Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
CA2808646C
(en)
|
2003-09-17 |
2016-08-23 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Thalidomide analogs as tnf-alpha modulators
|
US7612096B2
(en)
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
NZ550026A
(en)
|
2004-03-22 |
2009-10-30 |
Celgene Corp |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
WO2005112928A1
(en)
*
|
2004-05-05 |
2005-12-01 |
Celgene Corporation |
Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
|
ZA200702382B
(en)
|
2004-09-03 |
2008-08-27 |
Celgene Corp |
Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
|
CA2612612C
(en)
|
2005-06-30 |
2014-03-11 |
Celgene Corporation |
Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
|
EP1919500A2
(en)
|
2005-07-13 |
2008-05-14 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
KR20080042158A
(ko)
|
2005-08-31 |
2008-05-14 |
셀진 코포레이션 |
이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
|
ES2359162T3
(es)
|
2005-09-01 |
2011-05-19 |
Celgene Corporation |
Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas.
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
|
KR20080097190A
(ko)
*
|
2005-12-29 |
2008-11-04 |
안트로제네시스 코포레이션 |
태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
|
US8426355B2
(en)
|
2006-03-15 |
2013-04-23 |
Theralogics, Inc. |
Methods of treating muscular wasting diseases using NF-κB activation inhibitors
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
WO2008021391A1
(en)
|
2006-08-15 |
2008-02-21 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
MX2009001989A
(es)
*
|
2006-08-30 |
2009-03-09 |
Celgene Corp |
Compuestos de isoindolina 5-substituidos.
|
PL2420498T3
(pl)
|
2006-09-26 |
2017-10-31 |
Celgene Corp |
5-podstawione pochodne chinazolinonu jako środki przeciwnowotworowe
|
EP1923053A1
(en)
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
US8071135B2
(en)
|
2006-10-04 |
2011-12-06 |
Anthrogenesis Corporation |
Placental tissue compositions
|
WO2008057162A2
(en)
|
2006-10-06 |
2008-05-15 |
Anthrogenesis Corporation |
Native (telopeptide) placental collagen compositions
|
CN101952272B
(zh)
|
2007-09-26 |
2014-08-27 |
细胞基因公司 |
6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
|
KR20210022148A
(ko)
|
2007-09-28 |
2021-03-02 |
안트로제네시스 코포레이션 |
인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
|
US20090088393A1
(en)
*
|
2007-09-28 |
2009-04-02 |
Zomanex, Llc |
Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
|
AU2008325140A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Celgene Corporation |
Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
|
EP2235213A2
(en)
|
2007-12-20 |
2010-10-06 |
Celgene Corporation |
Use of micro-rna as a biomarker of immunomodulatory drug activity
|
MX2010009344A
(es)
*
|
2008-03-11 |
2012-09-28 |
Reddys Lab Ltd Dr |
Preparacion de lenalidomida.
|
WO2009111948A1
(zh)
*
|
2008-03-13 |
2009-09-17 |
天津和美生物技术有限公司 |
3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
|
US20110060010A1
(en)
*
|
2008-03-13 |
2011-03-10 |
Tianjin Hemay Bio-Tech Co., Ltd |
Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
SI2358697T1
(sl)
|
2008-10-29 |
2016-02-29 |
Celgene Corporation |
Spojine izoindolina za uporabo pri zdravljenju raka
|
DE102008057285A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
|
US9045453B2
(en)
|
2008-11-14 |
2015-06-02 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
DE102008057284A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
|
AU2009314568B2
(en)
*
|
2008-11-14 |
2016-01-21 |
Concert Pharmaceuticals Inc. |
Substituted dioxopiperidinyl phthalimide derivaties
|
DE102008057335A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Amorphes Lenalidomid
|
WO2010093434A1
(en)
|
2009-02-11 |
2010-08-19 |
Celgene Corporation |
Isotopologues of lenalidomide
|
EP3489352A1
(en)
|
2009-03-25 |
2019-05-29 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
ES2728776T3
(es)
|
2009-05-19 |
2019-10-28 |
Celgene Corp |
Formulaciones de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
CN101580501B
(zh)
*
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
US20120184746A1
(en)
|
2009-09-03 |
2012-07-19 |
Ranbaxy Laboratories Limited |
Process for the preparation of lenalidomide
|
WO2011050962A1
(en)
|
2009-10-29 |
2011-05-05 |
Ratiopharm Gmbh |
Acid addition salts of lenalidomide
|
CN102127054B
(zh)
*
|
2009-11-02 |
2013-04-03 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
CN101696205B
(zh)
|
2009-11-02 |
2011-10-19 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
WO2011069608A1
(en)
|
2009-12-09 |
2011-06-16 |
Ratiopharm Gmbh |
S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
|
CA2783616A1
(en)
|
2009-12-22 |
2011-06-30 |
Celgene Corporation |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
CA2786266A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
EP4289838A3
(en)
|
2010-02-11 |
2024-03-13 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
US8853175B2
(en)
|
2011-01-10 |
2014-10-07 |
Celgene Corporation |
Phenethylsulfone isoindoline derivatives and their use
|
PE20140983A1
(es)
|
2011-03-11 |
2014-08-25 |
Celgene Corp |
Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
|
US9090585B2
(en)
|
2011-03-28 |
2015-07-28 |
Deuterx, Llc |
2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
|
MX2013012083A
(es)
|
2011-04-18 |
2014-04-16 |
Celgene Corp |
Biomarcadores para el tratamiento de mieloma multiple.
|
KR20140024914A
(ko)
|
2011-04-29 |
2014-03-03 |
셀진 코포레이션 |
예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
MX356105B
(es)
|
2011-09-14 |
2018-05-14 |
Celgene Corp |
Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida.
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
HUE050327T2
(hu)
|
2011-12-27 |
2020-11-30 |
Amgen Europe Gmbh |
Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal
|
EP2817300B1
(en)
*
|
2012-02-21 |
2018-04-25 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
WO2013182660A1
(en)
|
2012-06-06 |
2013-12-12 |
Bionor Immuno As |
Hiv vaccine
|
ES2872967T3
(es)
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
AU2013299631B2
(en)
|
2012-08-09 |
2017-09-28 |
Celgene Corporation |
Salts and solid forms of (S)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
WO2014066243A1
(en)
|
2012-10-22 |
2014-05-01 |
Concert Pharmaceuticals, Inc. |
Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
FR2999914B1
(fr)
*
|
2012-12-21 |
2015-08-07 |
Oreal |
Utilisation de derives de l'acide imidocarboxylique pour traiter les alterations de la peau liees a l'age ou au photovieillissement
|
FR2999915B1
(fr)
*
|
2012-12-21 |
2017-08-11 |
Oreal |
Utilisation de derives de l'acide imidocarboxylique en tant qu'agent apaisant
|
WO2014110322A2
(en)
|
2013-01-11 |
2014-07-17 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
WO2014110558A1
(en)
|
2013-01-14 |
2014-07-17 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
AU2014215458A1
(en)
|
2013-02-05 |
2015-08-13 |
Anthrogenesis Corporation |
Natural killer cells from placenta
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
EP2970372B1
(en)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
CN104072476B
(zh)
*
|
2013-03-27 |
2018-08-21 |
江苏豪森药业集团有限公司 |
泊马度胺晶型及其制备方法和用途
|
AU2014254056B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
|
EP2815749A1
(en)
*
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
CN103497174B
(zh)
*
|
2013-07-29 |
2015-10-28 |
杭州派臣医药科技有限公司 |
泊利度胺的制备和精制方法
|
CN104557858B
(zh)
*
|
2013-10-29 |
2018-06-01 |
上海医药工业研究院 |
一种泊利度胺的制备方法
|
CN104557857A
(zh)
*
|
2013-10-29 |
2015-04-29 |
上海医药工业研究院 |
一种泊利度胺的纯化方法
|
JP6535670B2
(ja)
|
2013-12-03 |
2019-06-26 |
アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. |
ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ
|
CN104016967A
(zh)
*
|
2014-04-04 |
2014-09-03 |
南京工业大学 |
一种泊利度胺的合成方法
|
KR20240038809A
(ko)
*
|
2014-04-14 |
2024-03-25 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
CN109678840B
(zh)
*
|
2014-08-20 |
2023-12-01 |
河北菲尼斯生物技术有限公司 |
泊马度胺的制备方法
|
RS64038B1
(sr)
|
2014-08-22 |
2023-04-28 |
Celgene Corp |
Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima
|
CN105440013B
(zh)
*
|
2014-08-29 |
2018-10-09 |
杭州和泽医药科技有限公司 |
一种泊马度胺的制备方法
|
RU2695521C9
(ru)
*
|
2014-10-30 |
2019-08-19 |
Канпу Биофармасьютикалс, Лтд. |
Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение
|
WO2016097030A1
(en)
|
2014-12-19 |
2016-06-23 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide
|
EP3233082B1
(en)
|
2014-12-19 |
2018-12-05 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide
|
CN104447689B
(zh)
*
|
2014-12-22 |
2016-07-20 |
上海迈柏医药科技有限公司 |
来那度胺的晶型及其制备方法
|
KR20200052995A
(ko)
|
2015-01-20 |
2020-05-15 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
MX2017014567A
(es)
*
|
2015-05-22 |
2018-06-28 |
Biotheryx Inc |
Compuestos que tienen como dianas a proteinas, composiciones, metodos y usos de los mismos.
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN
|
WO2017109041A1
(en)
|
2015-12-22 |
2017-06-29 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
CA3038979A1
(en)
|
2016-10-11 |
2018-04-19 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
US11458123B2
(en)
|
2016-11-01 |
2022-10-04 |
Arvinas Operations, Inc. |
Tau-protein targeting PROTACs and associated methods of use
|
RU2750484C2
(ru)
|
2016-12-01 |
2021-06-28 |
Эрвинэс Оперейшнс, Инк. |
Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
WO2018108147A1
(zh)
|
2016-12-16 |
2018-06-21 |
康朴生物医药技术(上海)有限公司 |
一种组合、其应用及治疗方法
|
CA3047586A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas Operations, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
JP2020504741A
(ja)
|
2016-12-23 |
2020-02-13 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
Raf(急速進行性線維肉腫)ポリペプチドの標的分解のための化合物および方法
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
KR102125661B1
(ko)
|
2017-02-13 |
2020-06-22 |
강푸 바이오파마슈티칼즈 리미티드 |
전립선암 치료용 조합, 약학 조성물 및 치료 방법
|
PT3618842T
(pt)
|
2017-05-01 |
2024-01-12 |
Juno Therapeutics Inc |
Combinação de uma terapia celular e de um composto imunomodulador
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
US11413310B2
(en)
|
2017-06-02 |
2022-08-16 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
MX2019015155A
(es)
|
2017-06-29 |
2020-08-03 |
Juno Therapeutics Inc |
Modelo de raton para valorar toxicidades asociadas con inmunoterapias.
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
EP3505158A1
(en)
|
2017-12-27 |
2019-07-03 |
KRKA, d.d., Novo mesto |
Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
|
US11452722B2
(en)
|
2018-01-11 |
2022-09-27 |
Natco Pharma Limited |
Stable pharmaceutical compositions comprising lenalidomide
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
CA3092037A1
(en)
|
2018-02-21 |
2019-08-29 |
Celgene Corporation |
Bcma-binding antibodies and uses thereof
|
EP3545949A1
(en)
|
2018-03-29 |
2019-10-02 |
Midas Pharma GmbH |
Oral dosage forms comprising pomalidomide crystalline form a
|
KR20230130752A
(ko)
|
2018-04-04 |
2023-09-12 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
KR102259798B1
(ko)
|
2018-04-13 |
2021-06-02 |
주식회사 삼양홀딩스 |
붕해가 개선된 레날리도마이드의 경구용 정제 조성물
|
KR102286497B1
(ko)
|
2018-04-13 |
2021-08-05 |
주식회사 삼양홀딩스 |
다양한 용량의 레날리도마이드의 경구용 정제 조성물
|
KR102286500B1
(ko)
|
2018-04-13 |
2021-08-05 |
주식회사 삼양홀딩스 |
레날리도마이드를 포함하는 경구용 고형제제의 제조방법
|
WO2019199133A1
(ko)
|
2018-04-13 |
2019-10-17 |
주식회사 삼양바이오팜 |
레날리도마이드의 경구용 코팅 정제 조성물
|
JP2021518422A
(ja)
|
2018-04-13 |
2021-08-02 |
サムヤン バイオファーマシューティカルズ コーポレイションSamyang Biopharmaceuticals Corporation |
レナリドミドを含む医薬組成物
|
WO2020041331A1
(en)
|
2018-08-20 |
2020-02-27 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
US20220088070A1
(en)
|
2018-11-30 |
2022-03-24 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
WO2020118098A1
(en)
*
|
2018-12-05 |
2020-06-11 |
Vividion Therapeutics, Inc. |
Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
|
EP3917570A1
(en)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
WO2020227183A1
(en)
*
|
2019-05-03 |
2020-11-12 |
Dynamic Biologics Inc. |
Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
|
CN110343063A
(zh)
*
|
2019-08-09 |
2019-10-18 |
新乡双鹭药业有限公司 |
一种泊马度胺合成中杂质的制备方法
|
WO2021061644A1
(en)
*
|
2019-09-23 |
2021-04-01 |
Accutar Biotechnology Inc. |
Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
|
US11420956B2
(en)
|
2019-09-23 |
2022-08-23 |
Accutar Biotechnology Inc. |
Ureas having Androgen Receptor degradation activity and uses thereof
|
AU2020387392A1
(en)
|
2019-11-19 |
2022-07-14 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of Helios protein
|
BR112022012110A2
(pt)
|
2019-12-19 |
2022-12-13 |
Arvinas Operations Inc |
Compostos e métodos para a degradação direcionada de receptor androgênico
|
BR112022020897A2
(pt)
|
2020-04-15 |
2022-11-29 |
Tecnimede Soc Tecnico Medicinal Sa |
Forma de dosagem oral sólida compreendendo pomalidomida.
|
KR20230015933A
(ko)
|
2020-05-09 |
2023-01-31 |
아비나스 오퍼레이션스, 인코포레이티드 |
이작용성 화합물, 이작용성 화합물의 초순수 형태, 및 이를 포함하는 투여 형태를 제조하는 방법
|
MX2023008296A
(es)
|
2021-01-13 |
2023-09-29 |
Monte Rosa Therapeutics Inc |
Compuestos de isoindolinona.
|
AR125298A1
(es)
|
2021-04-06 |
2023-07-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
MX2023011940A
(es)
|
2021-04-16 |
2023-12-07 |
Arvinas Operations Inc |
Moduladores de la proteolisis bcl6 y metodos de uso asociados.
|
WO2023126531A1
(en)
|
2021-12-31 |
2023-07-06 |
A Fine House S.A. |
Lenalidomide oral solution
|
WO2023126530A1
(en)
|
2021-12-31 |
2023-07-06 |
A Fine House S.A. |
Oral solution comprising lenalidomide
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|